logo
Salesforce is using AI for up to 50% of its workload and its AI product is 93% accurate, says CEO Marc Benioff

Salesforce is using AI for up to 50% of its workload and its AI product is 93% accurate, says CEO Marc Benioff

Fast Company26-06-2025
Salesforce CEO and founder Marc Benioff said the company now relies on artificial intelligence for 30% to 50% of its entire workload.
The software giant, like many other tech companies in Silicon Valley, including Microsoft and Google, is going all in on the AI boom.
'All of us have to get our head around this idea that AI could do things, that before, we were doing, and we can move on to do higher value work,' Benioff told Bloomberg, including positions like software engineering and customer service. 'It's these agents, these digital laborers, digital employees who are out there doing this work servicing the customers, selling to the customer, marketing to the customer, partnering with me to do the analytics, do the marketing, the branding.'
Benioff said he even writes his yearly business plan with an AI partner, along with a 'human' Salesforce executive, adding the company was on track to have one billion of these 'agents' before the end of the year. (65% of companies are now experimenting with AI agents, according to an April KPMG survey.)
Benioff also estimated that Salesforce has reached 93% accuracy with the AI product it's selling to customers, including Walt Disney Co., which was developed to carry out tasks such as customer service without human supervision. Benioff added that it's not 'realistic' to reach 100% accuracy, and that other companies are at 'much lower levels because they don't have as much data and metadata.'
The software giant was ranked the No. 1 customer relationship management (CRM) software provider in 2025 for the 12th consecutive year; its clients include Apple, Boeing, Amazon, Walmart and McDonald's, just to name a few.
According to Bloomberg, AI is ushering in a new era of 'the tiny team.' Gone are the days when Silicon Valley companies rapidly hire as they scale; now tech companies are in a race to the bottom, competing to see who can manage the lowest headcount in an effort to cut costs, and increase efficiencies.
The AI boom comes at a time when many tech companies are slashing jobs, in part to keep up with inflation and increased economic uncertainty, spurred on by the Trump administration's tariffs, and conflict with Iran.
Salesforce by the numbers
Salesforce Inc. (NYSE:CRM) was trading up less than 1% on Thursday at the time of this writing in midday trading.
In the company's latest round of earnings for the first quarter, which ended April 30, the company reported revenue of $9.8 billion, up nearly 8% year-over-year, beating analyst expectations, and raised guidance 'by $400 million to $41.3 billion at the high end of the range.' Earnings per share (EPS) came in at $2.58, topping estimates of $2.55 by $.03.
Benioff said Salesforce has 'built a deeply unified enterprise AI platform—with agents, data, apps, and a metadata platform… with Agentforce, Data Cloud, our Customer 360 apps, Tableau, and Slack all built on one trusted, unified foundation, [so] companies of every size can build a digital labor force—boosting productivity, reducing costs, and accelerating growth.'
The company had a market capitalization of $257 billion at the time of this writing. Its next earnings report is scheduled for late August.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings
Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time28 minutes ago

  • Yahoo

Hologic (HOLX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Medical technology company Hologic (NASDAQ:HOLX) will be reporting earnings this Wednesday afternoon. Here's what investors should know. Hologic met analysts' revenue expectations last quarter, reporting revenues of $1.01 billion, down 1.2% year on year. It was a slower quarter for the company, with a slight miss of analysts' full-year EPS guidance estimates and full-year revenue guidance meeting analysts' expectations. Is Hologic a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hologic's revenue to be flat year on year at $1.01 billion, slowing from the 2.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.05 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hologic has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 0.9% on average. Looking at Hologic's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. Hologic is up 2.8% during the same time and is heading into earnings with an average analyst price target of $69.93 (compared to the current share price of $66.99). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio

CONMED (CNMD) Q2 Earnings: What To Expect
CONMED (CNMD) Q2 Earnings: What To Expect

Yahoo

time28 minutes ago

  • Yahoo

CONMED (CNMD) Q2 Earnings: What To Expect

Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here's what to look for. CONMED beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $321.3 million, up 2.9% year on year. It was a very strong quarter for the company, with a solid beat of analysts' full-year EPS guidance estimates and an impressive beat of analysts' EPS estimates. Is CONMED a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting CONMED's revenue to grow 1.9% year on year to $338.3 million, slowing from the 4.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.12 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. CONMED has missed Wall Street's revenue estimates three times over the last two years. Looking at CONMED's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.8%, beating analysts' expectations by 3.4%, and Intuitive Surgical reported revenues up 21.4%, topping estimates by 3.7%. Boston Scientific traded up 2.9% following the results while Intuitive Surgical was down 1.9%. Read our full analysis of Boston Scientific's results here and Intuitive Surgical's results here. Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. CONMED is down 4% during the same time and is heading into earnings with an average analyst price target of $66.60 (compared to the current share price of $50.02). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings
Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Yahoo

time28 minutes ago

  • Yahoo

Kraft Heinz (KHC) Reports Q2: Everything You Need To Know Ahead Of Earnings

Packaged foods company Kraft Heinz (NASDAQ:KHC) will be reporting results this Wednesday before market open. Here's what investors should know. Kraft Heinz met analysts' revenue expectations last quarter, reporting revenues of $6.00 billion, down 6.4% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' EBITDA estimates but full-year EPS guidance missing analysts' expectations. Is Kraft Heinz a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Kraft Heinz's revenue to decline 3.1% year on year to $6.27 billion, in line with the 3.6% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.64 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Looking at Kraft Heinz's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lamb Weston delivered year-on-year revenue growth of 4%, beating analysts' expectations by 5.7%, and McCormick reported flat revenue, in line with consensus estimates. Lamb Weston traded up 19.3% following the results while McCormick was also up 3.6%. Read our full analysis of Lamb Weston's results here and McCormick's results here. There has been positive sentiment among investors in the shelf-stable food segment, with share prices up 3.8% on average over the last month. Kraft Heinz is up 9.3% during the same time and is heading into earnings with an average analyst price target of $30.18 (compared to the current share price of $28.22). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store